Quantcast
Last updated on April 19, 2014 at 21:20 EDT

Latest Paracetamol Stories

2013-03-19 12:27:43

NASHVILLE, Tenn., March 19, 2013 /PRNewswire/ -- The first two installations of Apoteca in the United States took place at the Cleveland Clinic and Wake Forest University Baptist Medical Center. Cleveland Clinic's implementation plan included a lengthy review and approval by the Ohio Board of Pharmacy. Both facilities deployed Apoteca in busy oncology centers serving both inpatients and outpatients. Daily production includes complex doses that require reconstitution, multiple vials, bags...

2013-03-12 08:28:54

SAN DIEGO, March 12, 2013 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), announced today that the Department of Veterans Affairs has made OFIRMEV(®) (acetaminophen) injection available on the VA National Formulary (VANF). The VANF is a list of products (drugs and supplies) generally covered under VA pharmacy benefits. VANF products must be available for prescription at all VA facilities. The purpose of the VANF management process is to provide high quality, best value...

2013-03-06 20:22:11

SAN DIEGO, March 6, 2013 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, today announced a new supply agreement with Laboratorios Grifols, S.A. for the development, manufacture and supply of commercial quantities of OFIRMEV (acetaminophen) injection in flexible plastic bags. Previously, Cadence announced the extension of...

2013-03-05 08:28:30

MISSISSAUGA, ON, March 5, 2013 /PRNewswire/ - Nuvo Research Inc. (Nuvo) (TSX:NRI) announced today that its U.S. licensing partner, Mallinckrodt, the Pharmaceuticals Business of Covidien (NYSE:COV), has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) following the review of Mallinckrodt's New Drug Application (NDA) for diclofenac sodium topical solution, 2% w/w (PENNSAID 2%). In the letter, the FDA requires that Mallinckrodt successfully...

2013-03-04 12:28:46

Relmada Therapeutics announces the approval of its CTA (Clinical Trial Authorization) by the MHRA (Medicines and Healthcare products Regulatory Agency) in the United Kingdom to conduct a Phase 1 pharmacokinetic study with LevoCap ER. BLUE BELL, Pa., March 4, 2013 /PRNewswire/ -- Relmada Therapeutics, Inc., a clinical-stage company developing novel therapies for the treatment of chronic pain, today announced the approval of the application of a Clinical Trial Authorization (CTA) that...

2013-03-04 08:29:49

Regeneron receives 4% to 15% royalty on sales of Ilaris TARRYTOWN, N.Y., March 4, 2013 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will receive an additional potential royalty stream now that the European Commission (EC) has approved Novartis' llaris (canakinumab, ACZ885) in the treatment of patients with acute gouty arthritis who suffer frequent attacks, and whose symptoms cannot or should not be managed with current treatment options....

2013-03-03 23:03:21

The possibility of the federal court system consolidating cases filed by victims suffering liver problems from Tylenol has generated increased numbers of inquiries about legal representation. San Diego CA (PRWEB) March 03, 2013 http://www.resource4thepeople.com/defectivedrugs/acetaminophen.html Resource4thePeople announced today that it is informing consumers who may have suffered liver damage as a result of the use of Tylenol and other acetaminophen medications that an important court date...

2013-02-28 08:29:28

-Trial Further Assessing Efficacy of Neovasc Reducer(TM) in Treatment of Refractory Angina Expected to Complete Patient Enrollment in Coming Months-   -Company Also Announces Issuance of Incentive Options to Directors, Management and Staff- TSX Venture Exchange: NVC VANCOUVER, Feb. 28, 2013 /PRNewswire/ - Neovasc Inc. (TSXV: NVC) today announced that the clinical protocol for its COSIRA (coronary sinus reducer for treatment of refractory angina) trial has been published in...

2013-02-26 08:28:13

SAN FRANCISCO, Feb. 26, 2013 /PRNewswire/ -- AstraZeneca today announced high-level results from KODIAC-08, an open-label, randomised, 52-week, long-term safety trial of naloxegol versus usual care (UC) in patients with non-cancer related pain and opioid-induced constipation (OIC). UC was defined as the investigator's choice of an existing laxative treatment regimen for OIC. This is the fourth trial in the naloxegol Phase III development programme, and was designed to evaluate the long-term...

2013-02-22 08:23:42

MUMBAI, India and BALTIMORE, February 22, 2013 /PRNewswire/ -- Approval to add to growing SUPRAX(R) Franchise Pharma major, Lupin Ltd., announced today that its subsidiary, Lupin Pharmaceuticals Inc. (collectively, Lupin) has received approval for SUPRAX(R) (Cefixime) for Oral Suspension, 500 mg/5mL from the United States Food and Drugs Administration (FDA). Lupin expects to commence shipping the product in the near future. The approval will expand Lupin's range of...